Navigation Links
Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
Date:1/10/2011

Company's intention to present at the 29th Annual J.P. Morgan Healthcare Conference; anticipated net revenues for 2011; and products in development for Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2009 and in Auxilium's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... regarding the notice it received on May 21, 2015 ... the Company was below certain of the Exchange,s continued ... 1101 of the NYSE MKT Company Guide, due to ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Cepheid (NASDAQ: CPHD) ... Officer, received the Ernst & Young Entrepreneur Of The ... category. According to Ernst & Young LLP, the award ... in such areas as innovation, financial performance and personal ...
... 28, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... Russell 3000®, Russell 2000® and Russell Global Indexes posted by ...   Annual reconstitution of Russell,s U.S. indexes captures ... May, ranking them by total market capitalization. Membership in the ...
Cached Medicine Technology:Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 2Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 3Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 2Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 3
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating ... Lines ." It's for women interested in improving their love lives using specific ... which officially launched to the public early this morning, has drawn praise from ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth ... 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 in ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 , ... ... County, Los Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare ... new rating system of home health care providers. 24/7 Care At Home’s agency is ...
(Date:7/30/2015)... Melbourne, FL (PRWEB) , ... July 30, 2015 , ... ... Central Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This ... years, Dr. Clevens has worked closely with the university, developing a strong presence and ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health ... 2015 Special Olympics World Games, the largest sports and humanitarian event in the world ... Games. , The World Games, held July 25 through August 2, 2015, benefited from ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... The E2F family of genes is thought to play a ... these genes carry out their function and interact with one ... repressor genes are essential for a functional placenta and for ... COLUMBUS, Ohio Two particular repressor genes in a family ...
... halting cancer progression by exploiting a previously unrecognized "addiction" ... published by Cell Press online on April 16th in ... critical for tumor development and survival, and describes a ... Many cancers are associated with the loss of ...
... April 15 (HealthDay News) -- Genes that increase or reduce ... been identified by an international team of scientists. ... genes that may explain individual differences in brain size and ... senior author Paul Thompson, a professor of neurology at the ...
... 16 (HealthDay News) -- Large differences exist in the levels ... the United States and other developed countries, a new study ... 2,100 food items in seven product categories sold by Burger ... Subway in the United States, Canada, Australia, France, New Zealand ...
... full-contact football appear to be rising, especially among high ... The increase is alarming and indicates more coaches and ... skills of the game, according to researchers based at ... Until recently, the number of football-related brain injuries with ...
... will share the latest clinical research with addiction ... during the April 19th Blending Conference in Atlanta, ... Institute on Drug Abuse (NIDA), part of the ... American Society of Addiction Medicine Annual Medical-Scientific Conference ...
Cached Medicine News:Health News:2 repressor genes identified as essential for placental development 2Health News:Therapy exploits 'addiction' of leukemia cells 2Health News:Researchers ID Genes That May Determine Mental Illness 2Health News:Fast Food Is Saltier in U.S. Than Overseas 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: